经导管深静脉动脉化与标准治疗在无选择慢性肢体威胁性缺血患者中的比较
本研究通过倾向性匹配比较PROMISE II研究中接受经导管深静脉动脉化(TADV)的无选择慢性肢体威胁性缺血(CLTI)患者与CLariTI自然病程登记中未治疗患者。6个月无截肢生存率在PROMISE II组为66.1%,在CLariTI无选择队列为39.1%,倾向调整后绝对风险差改善29%(P < 0.0001),相对事件率降低45%。作者认为TADV似乎是一种有前景的治疗方法。
要点
- 无选择CLTI患者中,TADV组6个月无截肢生存率为66.1%,未治疗无选择队列为39.1%。
- 倾向调整后TADV组无截肢生存率绝对改善29%(P < 0.0001),相对事件率降低45%。
- 作者认为TADV在无选择CLTI患者中似乎是一种有前景的治疗方法。
核心结论
- 经导管深静脉动脉化(TADV)改善了无选择CLTI患者的6个月无截肢生存率,似乎是一种有前景的治疗方法。
研究设计与样本
- 采用倾向性匹配比较PROMISE II前瞻性研究中接受TADV干预的患者与同时入组CLariTI自然病程登记、不适合PROMISE II的CLTI患者。
- 未治疗的CLariTI无选择患者可为无选择或不符合PROMISE II入组标准者。
- 组间风险差采用common risk difference计算,P值由倾向评分分层Mantel-Haenszel检验提供,主要终点为无截肢生存率(AFS)。
主要发现
- 糖尿病见于超过75%的患者,所有患者均有组织缺损,35-46%有广泛组织缺损(Rutherford 6)。
- 6个月未调整AFS的Kaplan-Meier估计:PROMISE II患者(n = 105)为66.1%,CLariTI无选择队列(n = 121)为39.1%,全队列(无选择与不符合入组标准者合并,n = 180)为44.0%。
- 接受TADV治疗的无选择CLTI患者与无选择对照患者相比,倾向调整后AFS绝对风险差改善29%(P < 0.0001),相对事件率降低45%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with no-option chronic limb-threatening ischemia (no-option CLTI) have limited therapeutic options. The PROMISE II study evaluated, transcatheter arterialization of deep veins (TADV) as a treatment option for no-option CLTI. In the current study patients from PROMISE II were compared to patients from a registry of untreated no-option CLTI patients (CLariTI: Natural Progression of High-Risk Chronic Limb-Threatening Ischemia). METHODS: We used propensity matching to compare patients from the PROMISE II prospective study of the TADV intervention with simultaneously enrolled CLTI patients that were note candidates for PROMISE II but were enrolled in to CLariTI natural history registry. Untreated no-option CLTI (CLariTI) patients could either be no-option or patients who did not meet PROMISE II entry criteria. Risk difference between groups was calculated using common risk difference and P values were provided by propensity-score stratified Mantel-Haenszel test. The primary endpoint was amputation-free survival (AFS). RESULTS: Diabetes was present in over 75% of patients. All patients had tissue loss and 35-46% had extensive tissue loss (Rutherford 6). The unadjusted AFS at 6 months, was 66.1% by Kaplan-Meier estimate for PROMISE II patients (n = 105) compared to 39.1% in the no-option cohort of CLariTI (n = 121) and 44.0% in the full cohort (no-option and patients not meeting entry criteria combine, n = 180). The treatment group who underwent TADV for no-option CLTI had an absolute difference of 29% improved (P < 0.0001) propensity-adjusted risk difference in AFS and a relative event rate reduction of 45% compared to the no-option control patients. CONCLUSIONS: Transcatheter arterialization of deep veins (TADV) resulted in improved 6 month AFS in no-option CLTI patients and appears to be a promising therapy in patients with no-option CLTI.
引用
- Powell RJ, Mullin CM, Clair DG, et al. Comparison of Transcatheter Arterialization of Deep Veins to Standard of Care in Patients with No-Option Chronic Limb Threatening Ischemia. Ann Vasc Surg. 2023. PMID: 37858666. doi:10.1016/j.avsg.2023.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。